Headquartered in the Cayman Islands, Theravance Biopharma (TBPH) is a biopharmaceutical company focused on therapeutic areas such as infectious, respiratory, gastrointestinal, cardiovascular, renal, inflammation and immunology diseases.
The company attributes its current revenues to the product sales of the single commercialized product, Vibativ, and to upfront and milestone payments from partners such as Johnson & Johnson (JNJ) and Alfasigma S.p.A.
Today, many things seem to be working in favor of Theravance Biopharma. The company has projected FY 2018 operating loss guidance in the range of $180 million-$200 million. This is